Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug formulations tested in healthy volunteers

NCT ID NCT06911567

First seen Jan 19, 2026 · Last updated Jun 23, 2026 · Updated 28 times

Summary

This study tested different versions of the drug TEV-56286 (emrusolmin) in 47 healthy adults to see how well the body absorbs each form. Participants took a single dose of either a new formulation or a reference capsule, and researchers measured drug levels in the blood. The goal was to compare the formulations and check for any safety issues over about 70 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Teva Investigational Site 12141

    Miramar, Florida, 33025, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Emrusolmin (TEV-56286)

What this could lead to

If successful, this could help determine the best way to deliver emrusolmin in future studies, potentially leading to better treatments for conditions it targets.

What could go wrong

This is an early-stage trial in healthy volunteers, not patients. It only measures drug levels and short-term safety, so it cannot predict if the drug will work for any disease.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.